Type 2 diabetes patients often have high blood sugar while fasting—here's why

by Manuel Vázquez Carrera, The Conversation

edited by Gaby Clark, reviewed by Andrew Zinin

Gaby Clark

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

trusted source

written by researcher(s)

proofread

The GIST Add as preferred source

Many patients with type 2 diabetes wonder how their blood sugar levels can be high when they have not eaten anything. The answer to this counterintuitive phenomenon lies in what is known as insulin resistance.

Insulin resistance prevents cells from taking up glucose properly, but it also causes the liver to continue producing it. Here, we will look at how this happens and at what current research is being carried out to treat this condition.

Available energy

Generally speaking, our blood glucose levels are regulated by a balance between the intake of this type of sugar from food and its uptake by tissues. This balance mainly depends on the hormone insulin.

After a meal, a rise in blood glucose causes the beta cells of the pancreas to secrete insulin. This hormone facilitates the absorption, utilization and storage of glucose by body tissue, ensuring that the body has energy available when it needs it.

However, if we go many hours without eating, the body still has to maintain a minimum level of blood glucose. This is to prevent hypoglycemia (low blood sugar) and to ensure that energy is supplied to the tissues—particularly the brain, which depends almost exclusively on glucose.

In the first few hours of fasting, the liver produces glucose by breaking down reserves of glycogen, the form in which glucose is stored in the body. As fasting continues and glycogen is depleted, the liver begins to synthesize glucose from non-carbohydrate precursors, a process known as gluconeogenesis.

This mechanism is essential, as it ensures that our organs—and above all the brain—continue to function while we are fasting.

The broken lock

Type 2 diabetes completely disrupts the normal regulation of blood glucose levels because it causes patients to develop insulin resistance.

A simple way to explain this is to imagine insulin as a key that unlocks the door to the cells so that glucose can enter and be used for energy. In a healthy person, the key fits the lock perfectly. The door opens, and the glucose passes from the blood into the cells.

But in patients with insulin resistance, the lock is faulty. Although the body produces the hormone and there are keys available, the door does not open wide enough. The result is that some of that glucose cannot enter the cells. Instead, it accumulates in the blood, causing chronic hyperglycemia (high blood sugar).

But this is not insulin's only purpose. Another of its key functions is to curb glucose production in the liver—a process known as hepatic gluconeogenesis.

In type 2 diabetes, insulin resistance prevents insulin from doing this properly, causing the liver to continue producing glucose even when it is not needed. The result is that blood glucose levels stay high, even on an empty stomach.

It has been reported that levels of hepatic gluconeogenesis in people with type 2 diabetes may be anywhere from 40% to 200% higher than in healthy individuals.

For this reason, reducing hepatic glucose production has become a promising way to improve the effectiveness of currently available treatments to reduce blood sugar levels.

New treatment goals

One of the possible keys to controlling excessive glucose production by the liver in type 2 diabetes is a stress molecule called GDF15. Mice lacking this molecule show increased hepatic gluconeogenesis, suggesting that regulating its levels could help curb glucose production in the liver.

Previous studies in patients with type 2 diabetes have shown that treatment with metformin—the most commonly prescribed antidiabetic drug for treating type 2 diabetes, which acts primarily by inhibiting hepatic gluconeogenesis—also increases GDF15 levels.

This suggests that part of the drug's antidiabetic effect could be explained by its ability to raise GDF15 levels and, in doing so, reduce glucose production in the liver. Our research group recently observed that this effect is not seen in GDF15-deficient mice.

Furthermore, in our latest study, we observed that metformin fails to increase blood levels of this molecule in mice that lack the PPARβ/δ receptor. This is likely because PPARβ/δ is crucial for the maturation of GDF15 and, consequently, for the increase in its blood levels.

Taken together, these findings gradually reveal the key determinants of GDF15's regulation and function, offering promising new avenues for improving glucose control in patients with type 2 diabetes.

Key medical concepts

Diabetes Type 2Insulin ResistanceGDF15 GeneMetformin

Clinical categories

EndocrinologyCommon illnesses & Prevention Provided by The Conversation Who's behind this story?

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Citation: Type 2 diabetes patients often have high blood sugar while fasting—here's why (2026, June 24) retrieved 24 June 2026 from https://medicalxpress.com/news/2026-06-diabetes-patients-high-blood-sugar.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.